Author:
Mottet N.,Bellmunt J.,Bolla M.,Joniau S.,Mason M.,Matveev V.,Schmid H.P.,van der Kwast T.,Wiegel T.,Zattoni F.,Heidenreich A.
Reference90 articles.
1. EAU guidelines on prostate cancer;Heidenreich;Eur Urol,2008
2. Modified from Oxford Centre for Evidence-Based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, and Martin Dawes since November 1998. CEBM. Disponible en: http://www. pdptoolkit.co.uk/Files/ebm/cebm/Doing%20ebm/levels_of_evidence. htm (consultado en noviembre de 2010).
3. Hormonal therapy: historical perspective to future directions;McLeod;Urology,2003
4. Single-therapy an-drogen suppression in men with advanced prostate cancer: a systematic review and meta-analysis;Seidenfeld;Ann Intern Med,2000
5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献